Israeli pharmaceutical company Teva has received fast-track designation from the US Food and Drug Administration (FDA) for its experimental drug ecupitorin, which is being developed to treat Tourette syndrome in children. The accelerated review pathway is typically reserved for medicines that address serious conditions and demonstrate the potential to provide significant clinical advantages over existing treatments.Tourette syndrome is a neurological condition characterised by involuntary tics—both vocal and motor—that typically emerge in childhood. The condition can significantly impact quality of life, affecting education, social development, and daily functioning. Current treatment options remain limited, with many patients receiving only symptomatic relief rather than addressing the underlying cause.If approved, ecupitorin would represent a major advancement in Tourette treatment, introducing a novel mechanism of action that has not been seen in this therapeutic area for over five decades. This mechanism represents a fundamentally different approach to managing the condition, offering hope for patients and families who have had limited options. The fast-track designation indicates that Teva’s early clinical data showed promising results warranting accelerated development and review.The FDA’s decision to grant fast-track status underscores the significant unmet medical need in Tourette syndrome treatment, particularly for paediatric patients. Teva’s development of ecupitorin positions the Israeli company as a potential leader in addressing a condition that affects approximately one in 100 children worldwide.

Source: Maariv — Original article in Hebrew.